Episodebeskrivelse
How could Schedule III rescheduling affect cannabis tax planning? On this episode of Let’s Talk Tax, Dave McGuire speaks with David Seibel, EA, about the potential federal tax implications of rescheduling certain medical cannabis products, including Section 280E, R&D tax credits, and depreciation opportunities.
They discuss how eligible medical cannabis businesses may be affected by changes to expense deductions and federal credits, what cultivation and processing activities may warrant an R&D review, and how bonus depreciation and qualified production property could factor into investment…
Nettsted: podcasters.spotify.com

